NAN Nanoscience

    Embargoed Release: 07:00hrs Friday 30 November 2007

                               Nanoscience Inc.                                

                        (`Nanoscience' or the `Group')                         

                Strategic Development and Distribution Alliance                

Nanoscience is pleased to announce that its wholly owned subsidiary, Toumaz
Technology Limited (`Toumaz'), has entered into a Strategic Development and
Distribution Alliance (the `Alliance') with a leading global medical devices
business (the `Strategic Partner'). Through the Alliance it is intended that
the two parties will develop agreed solutions, incorporating Toumaz's Amx(tm)
technology and its Sensium platform, that will be sold into global healthcare
markets with the objective of becoming global leaders in handheld and body worn
wireless diagnostic and monitoring products. It is envisaged that these next
generation monitoring products will be disposable, non invasive and capable of
providing real time critical vital sign information. From the inception of the
Alliance Toumaz will receive funds from its Strategic Partner for further
development work.

Furthermore, the Strategic Partner has committed to provide funding and
resources to assist in gaining any necessary regulatory approvals and will
carry out global manufacturing, product marketing, sales and distribution.

The Directors of Nanoscience estimate, on the basis of existing market data,
that the vital sign monitoring market already exceeds $1.5bn and continues to
grow, whilst the Point of Care diagnostics worldwide market is estimated at
$10bn and growing.

Toumaz will retain all the background intellectual property relating to its AMx
(tm) platform and will be entitled to explore further revenue streams for the
technology outside of the field of use being exploited jointly with its
Strategic Partner.

It is anticipated that ongoing success within the program will result in a
growing financial and technical commitment from Toumaz's Strategic Partner and
the Board look forward to reporting on further progress in the first half of
next year.

Nanoscience has provided Toumaz with ongoing research and development funding
and has continued to work closely alongside its management team to provide the
additional commercial and corporate expertise that has resulted in the
establishment of this landmark alliance.

Chris Toumazou, Chairman of Toumaz Technology Limited, commented:

`The establishment of this alliance is a very positive development for Toumaz,
and we now have the opportunity to provide end to end solutions in the
personalized healthcare space. This has been a key strategic goal of the
business that we now believe is deliverable.'

Guy Spelman, Nanoscience's CEO, commented:

`This is the most significant landmark in the seven year history of Toumaz as
the road to commercialisation is now visible and we look forward to reporting
on further progress throughout 2008.'

                                    -Ends-                                     

Further information:

Guy Spelman               Nanoscience Inc.          07767 338 967            
                                                                             
Simon Raggett             Strand Partners Limited   0207 409 3494            
                                                                             
Matthew Chandler                                                             
                                                                             
Andrew Tan                Hansard Group             020 7245 1100            
                                                                             
www.hansardgroup.co.uk                                                       

About Nanoscience Inc.:

Nanoscience is a specialist niche investor in emerging technologies with a
strong commercial proposition from within the medical technology and
semiconductor sectors.

About Toumaz (www.toumaz.com):

Toumaz, winner of the first prize at the fifth Oracle Partner Network (OPN)
Innovation Awards for Europe, the Middle East and Africa and the IET Innovation
Award for Electronics 2007 is a developer of advanced RF, analogue and mixed
signal semiconductors. The focus of the business is low power devices based on
the company's proprietary AMx(tm) (Advanced Mixed Signal) technology which
addresses the needs of lower power consumption for mobile and wirelessly
connected systems.



END

Nanoscience (LSE:NAN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Nanoscience (LSE:NAN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024